US-20260125461-A1 - Nanobody targeting IL-23A and application thereof

Abstract

The present invention discloses a nanobody targeting IL-23A and an application thereof, and relates to the technical field of biological medicine. The nanobody VVH1 includes framework regions and complementary determining regions; the framework regions include VVH1FR-H1, VVH1FR-H2, VVH1FR-H3 and VVH1FR-H4, and the amino acid sequences of VVH1FR-H1, VVH1FR-H2, VVH1FR-H3 and VVH1FR-H4 are respectively shown as SEQ ID NOs. 4-7; and the complementary determining regions include VVH1CDR-H1, VVH1 CDR-H2 and VVH1 CDR-H3, and the amino acid sequences of VVH1 CDR-H1, VVH1 CDR-H2 and VVH1 CDR-H3 are respectively shown as SEQ ID NOs. 1-3. The nanobody has high binding activity with IL-23A, has the characteristics of small molecular weight, good stability, good tissue wettability, weak immunogenicity and the like compared with a traditional antibody, and can be applied to the preparation of an antibody drug targeting IL-23A so as to treat related diseases through combination with IL-23A.

Inventors

• Fan Zhang
• Jian Ma
• Lin Mei
• Jinxie ZHANG
• Ran Luo

Assignees

• Beijing MEBIO Biotechnology Co., Ltd.

Dates

Publication Date

20260507

Application Date

20250903

Priority Date

20241106

Claims (5)

1. 1 . A nanobody VVH1 targeting IL-23A, wherein the nanobody VVH1 comprises framework regions and complementary determining regions; the framework regions comprise VVH1 FR-H1, VVH1 FR-H2, VVH1 FR-H3 and VVH1 FR-H4, and the amino acid sequences of VVH1 FR-H1, VVH1 FR-H2, VVH1 FR-H3 and VVH1 FR-H4 are respectively shown as SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6 and SEQ ID NO. 7; and the complementary determining regions comprise VVH1 CDR-H1, VVH1 CDR-H2 and VVH1 CDR-H3, and the amino acid sequences of VVH1 CDR-H1, VVH1 CDR-H2 and VVH1 CDR-H3 are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3.
2. 2 . A coding gene, comprising the nanobody VVH1 according to claim 1 .
3. 3 . A recombinant vector, comprising the coding gene according to claim 2 .
4. 4 . A transformed cell, comprising the recombinant vector according to claim 3 .
5. 5 . (canceled)

Description

CROSS-REFERENCE TO SEQUENCE LISTING The Sequence Listing XML file entitled “SequenceListing_XML.xml,” created on Aug. 8, 2025, and having a size of 11,399 bytes, is incorporated herein by reference in its entirety pursuant to 37 C.F.R. 1.821 (c) (1). TECHNICAL FIELD The present invention relates to the technical field of biological medicine, and more particularly, to a nanobody targeting IL-23A and an application thereof. BACKGROUND ART IL-23, as a member of the IL-12 cytokine family, is a heterodimer pro-inflammatory cytokine composed of two subunits of IL-23A (p19) and IL-12/23B (sharing p40 with IL-12) which are bound by a covalent disulfide bond. In 2003, it was found that the two subunits of IL-23 had different functions, wherein IL-23A was mainly produced by macrophages and dendritic cells, and was also proved to have a capability of coordinating the activity of immune cells, thereby playing a key role in the pathogenesis of immune inflammatory diseases. A traditional antibody consists of two identical heavy-chain polypeptides and two identical light-chain polypeptides, wherein a heavy chain consists of one variable region and three constant regions, and a light chain consists of one variable region and one constant region. In 1993, Belgian scientist Hamers-Casterman and his team first reported a heavy-chain antibody found in camelid blood that naturally lacks light chains, which contains only one heavy-chain variable region (VHH) and two conventional constant regions. Single-domain antibodies each composed of only heavy-chain variable regions, also referred to as nanobodies (Nbs), may be obtained by cloning the variable region. As a novel antibody, the nanobody has small size and molecular weight, strong tissue permeability, weak immunogenicity and other biological characteristics, and also has production characteristics of low production cost, high yield, capability of being produced and expressed in a variety of microbial systems in large quantities and no need for post-translational modification, as well as the capability of specifically identifying some hidden epitopes and other application advantages, thereby laying a good foundation for clinical development or industrial production. Based on the above content, IL-23A may be used as a potential target for specific treatment of immune diseases, but the current clinical drug research on this target is still very limited, so the development of novel antibodies against this target is of great significance. SUMMARY OF THE INVENTION An object of the present invention is to provide a nanobody targeting IL-23A and an application thereof, to solve the above problems existing in the prior art. The nanobody has high binding activity with IL-23A, has the characteristics of small molecular weight, good stability, good tissue wettability, weak immunogenicity and the like compared with a traditional antibody, and can be applied to the preparation of an antibody drug targeting IL-23A. In order to fulfill the above object, the present invention provides the following technical solution: the present invention provides a nanobody VVH1 targeting IL-23A, wherein the nanobody VVH1 includes framework regions and complementary determining regions; the framework regions include VVH1 FR-H1, VVH1 FR-H2, VVH1 FR-H3 and VVH1 FR-H4, and the amino acid sequences of VVH1 FR-H1, VVH1 FR-H2, VVH1 FR-H3 and VVH1 FR-H4 are respectively shown as SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6 and SEQ ID NO. 7; and the complementary determining regions include VVH1 CDR-H1, VVH1 CDR-H2 and VVH1 CDR-H3, and the amino acid sequences of VVH1 CDR-H1, VVH1 CDR-H2 and VVH1 CDR-H3 are respectively shown as SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3. The present invention further provides a coding gene, including the above-mentioned nanobody VVH1. The present invention further provides a recombinant vector, including the above-mentioned coding gene. The present invention further provides a transformed cell, including the above-mentioned recombinant vector. The present invention further provides an application of the above-mentioned coding gene, recombinant vector or transformed cell in the preparation of the above-mentioned nanobody VVH1. The present invention further provides an application of the above-mentioned nanobody VVH1 in the preparation of an antibody drug targeting IL-23A. The present invention further provides an antibody drug targeting IL-23A, and an active ingredient includes the above-mentioned nanobody VVH1. Further, the antibody drug also includes pharmaceutically acceptable accessories. The present invention discloses the following beneficial effects. According to the present invention, after a large number of studies, the nanobody VVH1 targeting IL-23A is obtained by screening. This nanobody has high binding activity with IL-23A, has the characteristics of small molecular weight, good stability, good tissue wettability, weak immunogenicity and the like compared with a traditiona